Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development

Highlights ► Virus-like particles (VLPs) are a class of recombinant subunit vaccines. ► VLPs resemble native viruses but lack infectious genetic material. ► VLPs are promising vaccines due to strong immunogenicity and safety. ► VLPs can be produced in prokaryotic or eukaryotic expression systems, or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2012-12, Vol.31 (1), p.58-83
Hauptverfasser:	Kushnir, Natasha, Streatfield, Stephen J, Yusibov, Vidadi
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Aluminum Animal models Applied microbiology Avian flu Bacteria Biological and medical sciences Biotechnology Clinical development Cytotoxicity Deoxyribonucleic acid Development DNA E coli Expression vectors Fundamental and applied biological sciences. Psychology fungi Genetic engineering Hepatitis Heterologous expression system HIV Human immunodeficiency virus Human papillomavirus Humans immune response Immunogenicity Lipids Microbiology Molecular weight Pathogens production technology Proteins recombinant antigens recombinant proteins Review Structural proteins Subunit vaccine subunit vaccines Tropical diseases Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Virus-Like Particle - immunology Viral Vaccines - immunology Virosome Virosomes - immunology Virus-like particle Virus-like particles Viruses Yeast
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights ► Virus-like particles (VLPs) are a class of recombinant subunit vaccines. ► VLPs resemble native viruses but lack infectious genetic material. ► VLPs are promising vaccines due to strong immunogenicity and safety. ► VLPs can be produced in prokaryotic or eukaryotic expression systems, or in vitro . ► VLP-based vaccine candidates targeting many diseases are in clinical development.
ISSN:	0264-410X 1873-2518 1873-2518
DOI:	10.1016/j.vaccine.2012.10.083